Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories has launched Olanzapine tablets (2.5mg, 5mg, 7.5mg, 10mg, 15mg), a bioequivalent generic version of ZYPREXA tablets in the US market on April 23, 2012 following the approval by the United States Food & Drug Administration (USFDA) of the company's ANDA for Olanzapine tablets.

Dr. Reddy’s Olanzapine tablets in 20 mg had been awarded a 180-day period of marketing exclusivity in the US on October 26, 2011 which was commercialized through a commercial, manufacture and supply agreement with Teva Pharmaceutical Industries.

The ZYPREXA tablets brand and generic had combined US sales of approximately $3.28 billion for the most recent twelve months ending January 2012 according to IMS Health.

Dr. Reddy’s Olanzapine tablets in 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg strengths are available in 30 and 500 count bottles.